Products for Research Use Only
RegisterLogin

Flufenamic acid-13C6

CAT: 0804-HY-B1221S1-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-B1221S1-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Flufenamic acid-13C6 is the 13C6 labeled Flufenamic acid. Flufenamic acid is a non-steroidal anti-inflammatory agent, inhibits cyclooxygenase (COX), activates AMPK, and also modulates ion channels, blocking chloride channels and L-type Ca2+ channels, modulating non-selective cation channels (NSC), activating K+ channels. Flufenamic acid binds to the central pocket of TEAD2 YBD and inhibits both TEAD function and TEAD-YAP-dependent processes, such as cell migration and proliferation.
CAS Number
1325559-30-5
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
AMPK; Calcium Channel; Chloride Channel; COX; Isotope-Labeled Compounds; Parasite; Potassium Channel
Type
Isotope-Labeled Compounds
Related Pathways
Anti-infection; Epigenetics; Immunology/Inflammation; Membrane Transporter/Ion Channel; Neuronal Signaling; Others; PI3K/Akt/mTOR
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/flufenamic-acid-13c6.html
Purity
99.5
Solubility
10 mM in DMSO
Smiles
OC([13C]([13CH]=[13CH][13CH]=[13CH]1)=[13C]1NC2=CC(C(F)(F)F)=CC=C2)=O
Molecular Formula
C8 13C6H10F3NO2
Molecular Weight
287.19
Precautions
H302, H315, H319, H335
References & Citations
[1]Guinamard R, et al. Flufenamic acid as an ion channel modulator. Pharmacol Ther. 2013 May;138 (2) :272-84.|[2]Pobbati AV, et al. Targeting the Central Pocket in Human Transcription Factor TEAD as a Potential Cancer Therapeutic Strategy. Structure. 2015;23 (11) :2076-2086.|[3]Pongkorpsakol P, et al. Cellular mechanisms underlying the inhibitory effect of flufenamic acid on chloride secretion in human intestinal epithelial cells. J Pharmacol Sci. 2017 Jun;134 (2) :93-100.|[4]Pongkorpsakol P, et al. Flufenamic acid protects against intestinal fluid secretion and barrier leakage in a mouse model of Vibrio cholerae infection through NF-κB inhibition and AMPK activation. Eur J Pharmacol. 2017 Mar 5;798:94-104.|[5]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53 (2) :211-216.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported

Related Products

CatalogName
HY-B1221-01Flufenamic acid
HY-B1221R-01Flufenamic acid (Standard)
HY-B1221S-01Flufenamic acid-d4
HY-W747703-01Hippuric acid-13C6
HY-W771036Argininic acid-13C6
HY-W017522S1-01Adipic acid-13C6
HY-N1428S1-01Citric acid-13C6
HY-B0167S1-01Salicylic acid-13C6
HY-16637S5Folic acid-13C6
HY-W777477Homovanillic Acid-13C6

Alternative Products

CatalogName
T0858-01Flufenamic acid

Popular Products